Repligen Files S-4 for $1.5B BioLife Acquisition: 0.1442 Exchange Ratio, $11.25 Cash Per Share
RGEN sits 79% above its 52-week low of $100.99.
Summary
Repligen's S-4 registration statement details the terms of its $1.5 billion acquisition of BioLife Solutions: $11.25 cash plus 0.1442 Repligen shares per BioLife share, with closing expected in Q4 2026.
Key Events · M&A and Partnerships · RGEN
-
Merger Terms Finalized
BioLife stockholders to receive $11.25 cash plus 0.1442 Repligen shares per share, implying $31.00 per BioLife share at signing — a 17.6% premium to the unaffected price.
-
Deal Structure and Dilution
Approximately 7.3 million Repligen shares will be issued (36% cash / 64% stock mix), with BioLife holders owning ~11.2% of the combined company.
-
Regulatory and Closing Timeline
HSR waiting period expires September 3, 2026; closing expected Q4 2026 with outside date January 31, 2027 (extendable to July 30, 2027).
-
Termination Fee
$59 million termination fee payable by BioLife in certain circumstances, including accepting a superior proposal.
Analysis · RGEN · Life Sciences
This S-4 finalizes the terms of Repligen's $1.5 billion acquisition of BioLife Solutions, first announced July 22, 2026. BioLife stockholders will receive $11.25 in cash plus 0.1442 Repligen shares per BioLife share — a fixed exchange ratio implying $31.00 per share at signing, a 17.6% premium to BioLife's unaffected price. The deal is expected to close in Q4 2026, subject to HSR clearance (waiting period expires September 3, 2026) and BioLife stockholder approval. A $59 million termination fee protects Repligen. The transaction adds biopreservation media and cell processing products to Repligen's bioprocessing portfolio, with projected synergies of $22 million annually by 2028. For Repligen shareholders, the deal is dilutive — approximately 7.3 million new shares will be issued — but management expects the combination to expand its cell and gene therapy capabilities.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 43.9% of the 999 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.15%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RGEN was trading at $180.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.2B. The 52-week trading range was $100.99 to $188.73. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.